Mood drug trial for pancreatic cancer patients halted early
NCT ID NCT05289830
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the antidepressant escitalopram could reduce depression in people with localized pancreatic or related cancers who were receiving chemotherapy before surgery. Only 4 participants enrolled before the trial was stopped. The goal was to measure changes in depression scores and quality of life using surveys.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Blood and gut clues may flag pancreatic cancer risk early
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- A sound wave that could expose hidden pancreatic cancer?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?